Is there a shortage of Norditropin? Children with difficulty growing due to low or no growth hormone are treated with Norditropin. It is a prescription drug that includes human growth hormones. The most prevalent form of natural human growth hormone is chemically similar to the drug Norditropin-Nordilet injection. Children with developmental failure brought on by low endogenous growth hormone secretion are treated with it. Adults with low heights are also treated with it.
A leading global pharmaceutical company, Novo Nordisk, reported that there would be a Norditropin supply shortage in the upcoming months. Norditropin Flexpro and Norditropin Nordiflex growth hormone (somatropin) supplies will be constrained in 2023 due to production issues. Omnitrope SurePal, an alternative growth hormone medication, will be prescribed to youngsters instead. It functions similarly to Norditropin products. Other growth hormone-related products may be recommended for some kids.
DiscontinuedNews is impartial and independent, and every day, we create distinctive, world-class programs, news, and content that inform, educate and entertain millions of people worldwide.
Norditropin shortage 2023
The Department of Health and Social Care (DHSC) has published a medicine supply alert. This alert is made for Norditropin (somatropin) Flexpro 10 mg/1.5 ml and Norditropin (somatropin) NordiFlex 5 mg/1.5 ml, 10 mg/1.5 ml, and 15 mg/1.5 ml solutions for injection pre-filled pens.
They also announced that, until the beginning of February 2023, the Norditropin (somatropin) Flexpro 10 mg pen would be out of stock. After supplies are restocked, the availability of all dosages will be restricted for the rest of 2023. Also, it will only be available to patients who have been receiving this treatment for a while.
Also, Norditropin (somatropin) NordiFlex 5 mg, 10 mg, and 15 mg pens will run out of stock starting mid-February 2023. It will need to meet increased demand for the shortfall above. Omnitrope (somatropin) SurePal injectable cartridge solutions are now available. They can handle a total rise in demand at this time.
Norditropin FlexPro is currently temporarily out of stock, according to Novo Nordisk Limited, Ireland. This shortfall could result in patients receiving inadequate care. This is due to production delays, not to any issues with safety or hygiene. In early February 2023, Norditropin FlexPro 10 mg/1.5 mL is scheduled to arrive in Ireland, according to Novo Nordisk Ltd.
Who manufactures Norditropin?
Novo Nordisk Pharmaceuticals manufacture Norditropin. Novo Nordisk has assisted people suffering from growth hormone abnormalities for more than 40 years. Since 1995, the FDA has given Norditropin approval in the US. If doctors have recommended Norditropin, Novo Nordisk offers many options to help eligible patients get it.
Children with Turner syndrome, Noonan syndrome, or growth hormone deficit (GHD) are eligible to receive Norditropin. The generic version of Norditropin FlexPro is Somatropin, and Norditropin FlexPro is a drug with a registered trademark.
Is Norditropin discontinued?
According to Novo Nordisk, Norditropin SimpleXx (somatropin) cartridges with NordiPen injectable pens will be stopped in Ireland on July 31, 2021. Due to the creation of Norditropin FlexPro, which offers users a better injection sensation, the manufacture of Norditropin Simplexx has been discontinued.
Growth hormone is a group of steroid substances that are forbidden at all times and for all categories of athletes. These include elite, junior, and masters-level competitors. This is according to the World Anti-Doping Agency’s (WADA) Prohibited List. In the US, Norditropin is no longer sold under that brand name. They might be readily available if the FDA has authorized generic versions of this product.
This medicine’s most frequent side effects are rash, headaches, and injection site reactions. We should tell our doctor if these concern us or seem serious. There might be techniques to lessen or stop them.
Is Norditropin out of stock?
Due to a rise in demand and production difficulties, Norditropin is in short supply, according to Novo Nordisk. This shortfall does not affect other somatropin injectable formulations. All Norditropin FlexPro medications are only temporarily offered by Novo Nordisk.
Drug shortages frequently occur in the US, but more often when demand is low. David Margraf, a pharmaceutical research scientist, said that shortages “hit a wide range of patient populations with various drugs, but most of those don’t receive a lot of headline news because they’re very narrow.”
The causes of empty shelves in a drug store might change from place to place and from drug to drug at any moment. Every scarcity has unique contributing causes.
The adverse effects of Norditropin could be nasty. This involves an increased chance of the spread of cancer or the growth of an existing tumor. Also, it can raise the risk of cancer or tumor reappearance in those who received radiation therapy to the head or brain as children and have issues with low growth hormone.
Novo Nordisk Limited, Ireland, discovered a temporary supply shortage of Norditropin FlexPro 10 mg/1.5 ml on December 21, 2022. There may be a temporary shortfall of Norditropin FlexPro 10 mg/1.5 ml from roughly February 7 to February 19.